Company Overview and News

Thriven sees thriving growth as new projects kick in

2018-08-27 theedgemarkets
KUALA LUMPUR: Property developer Thriven Global Bhd, formerly known as Mulpha Land Bhd, is targeting an exponential growth in its top and bottom lines supported by unbilled sales of over RM460 million as well as new sales.

The Week Ahead: Keeping an eye on Mahathir’s China trip and July inflation

2018-08-20 theedgemarkets
The spotlight this week will be firmly on the outcome of Prime Minister Tun Dr Mahathir Mohamad’s first official visit to China from Aug 17 to 21.
0104 7889 7158 BSMAF 5168 7045 HRGHY 1818

Thriven up 1.11% on renewed buying interest

2018-08-09 theedgemarkets
KUALA LUMPUR (Aug 9): Thriven Global Bhd (Thriven) rose 1.11% this morning on renewed buying interest in the stock.

Renewed buying interest emerged in Thriven, says AllianceDBS Research

2018-08-08 theedgemarkets
KUALA LUMPUR (Aug 9): AllianceDBS Research said Thriven Global Bhd (Thriven) had on Aug 8 crossed over the 45 sen hurdle to reach an intraday high of 47.5 sen before settling at 45 sen (up 1 sen or 2.27%).

Land deals in the cross hairs

2018-08-06 theedgemarkets
JUST before May 9, a prominent personality tried to take over a 120-acre tract in Kuala Lumpur that was owned by the government. After much consultation, it was decided that the deal would be deferred until after the general election to avoid controversy.
7889 3905 8583 4022

Stocks on a high

AS expected, the stock market had a relatively wild ride on Monday, its first day of business following the momentous 14th General Election (GE14).
7293 0035 3026 7889 0107 BATS 4162 BSMAF 1481 1818

Old PM heralds hope for new corporate culture

In the spotlight: Many shed tears of joy when Dr Mahathir was sworn in as the seventh Prime Minister.
7889 5222

Stocks on the radar

Possible M&A: Shareholding changes suggest that Alliance Bank could be poised for an M&A down the road.
2488 3204 5226 7889 7078

Construction stocks and ringgit likely to be focus

PETALING JAYA: Amidst the easing of fears of political uncertainty, the performance of the ringgit and construction-related stocks is likely to be in focus when markets open on Monday.
3204 STAN 580001 STAB 7889 STAN STAC 2888 SCBFF 5263

Market up ahead of polls

Pre-election surge: The FBM KLCI was 1,846.51 points at the close yesterday, up 1 from Monday’s close prior to polling day. — AP
1155 1023 0035 5225 MLYBY 6888 7889 MLYNF AXXTF Q0F IHHHF CIMDF

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...